{
  "claims": [
    {
      "claim_id": "C01",
      "claim": "Intratumoral delivery of an mRNA vaccine induces a type I interferon-rich inflammatory state in tumours.",
      "strength": "moderate",
      "evidence": [
        {
          "quote": "The paper investigates whether intratumoral delivery of an mRNA vaccine can create an interferon-rich inflammatory state that improves sensitivity to anti-PD-L1 therapy.",
          "line_ref": "L11"
        },
        {
          "quote": "Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.",
          "line_ref": "L42"
        },
        {
          "quote": "| Type I interferon response score (normalized units) | 3.1 | 1.0 | Marked induction after mRNA vaccination in tumors |",
          "line_ref": "L31"
        }
      ],
      "caveat": "The report summarizes a mechanistic chain, but also notes that some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings (L53)."
    },
    {
      "claim_id": "C02",
      "claim": "mRNA vaccination is associated with increased antigen processing/presentation and a broader MHC-I peptide repertoire in tumours.",
      "strength": "moderate",
      "evidence": [
        {
          "quote": "Interferon-associated antigen processing and presentation pathways increase.",
          "line_ref": "L43"
        },
        {
          "quote": "A broader peptide repertoire appears on MHC-I, improving tumor visibility to T cells.",
          "line_ref": "L44"
        },
        {
          "quote": "| Fraction of proteins represented in MHC-I peptidome | 40.6% | 20.6% | Strong expansion of MHC-I-presented landscape |",
          "line_ref": "L29"
        }
      ],
      "caveat": "Mouse model effects may not map one-to-one to all human tumors, and some mechanistic readouts varied across model systems (L52-L53)."
    },
    {
      "claim_id": "C03",
      "claim": "In murine tumour models, combining intratumoral mRNA vaccination with anti-PD-L1 is described as improving tumour control and immune infiltration relative to baseline contexts.",
      "strength": "tentative",
      "evidence": [
        {
          "quote": "- Preclinical arm: multiple murine tumor models with intratumoral mRNA vaccine and anti-PD-L1 combinations.",
          "line_ref": "L14"
        },
        {
          "quote": "Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.",
          "line_ref": "L46"
        },
        {
          "quote": "| Intratumoral CD8+ T-cell density fold-change | 1.8x | 1.0x | Increased immune infiltration with combination therapy |",
          "line_ref": "L33"
        }
      ],
      "caveat": "The report notes that vaccine-only and ICI-only conditions had limited or non-durable effects in some settings (L36-L37), and mouse model results may not translate directly to human tumours (L52)."
    },
    {
      "claim_id": "C04",
      "claim": "In a retrospective metastatic patient cohort receiving ICI therapy, prior SARS-CoV-2 mRNA vaccination status was associated with improved survival.",
      "strength": "tentative",
      "evidence": [
        {
          "quote": "- Translational arm: a retrospective cohort of metastatic patients receiving ICI treatment, compared by prior SARS-CoV-2 mRNA vaccination status.",
          "line_ref": "L15"
        },
        {
          "quote": "| Retrospective human survival comparison p-value | p=0.01 | N/A | Vaccinated subgroup had improved survival under ICI treatment |",
          "line_ref": "L30"
        },
        {
          "quote": "Human retrospective metastatic cohort: 130 patients total.",
          "line_ref": "L21"
        }
      ],
      "caveat": "The human analysis is retrospective and non-randomized with likely residual confounding, and vaccination timing relative to ICI initiation varied across patients (L49-L50)."
    },
    {
      "claim_id": "C05",
      "claim": "The sensitization effect depends on mRNA and type I interferon signaling, based on perturbation and control conditions described.",
      "strength": "moderate",
      "evidence": [
        {
          "quote": "- Mechanistic probes: immunopeptidomics, transcriptomics, and perturbation controls (including IFNAR1 blockade and non-mRNA particle controls).",
          "line_ref": "L16"
        },
        {
          "quote": "- Lipid particle controls lacking mRNA did not reproduce the sensitization effect.",
          "line_ref": "L38"
        },
        {
          "quote": "- Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.",
          "line_ref": "L39"
        }
      ],
      "caveat": "The report frames these as controls/perturbations within preclinical settings; the extent to which the same dependency governs human outcomes is not established and mouse-to-human mapping is uncertain (L52)."
    }
  ]
}
